The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with a diagnosis of unresectable hepatocellular carcinoma

• Able to comprehend and provide written informed consent in accordance with institutional guidelines.

Locations
Other Locations
China
Beijing 302 Hospital
RECRUITING
Beijing
Hong Kong Special Administrative Region
Humanity & Health Medical Group Limited
RECRUITING
Hong Kong
Japan
Tokyo University
RECRUITING
Tokyo
Contact Information
Primary
Danny Wang, PhD
danny.wang@hnhmgl.com
+852-21160598
Time Frame
Start Date: 2018-07-16
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 5000
Related Therapeutic Areas
Sponsors
Collaborators: Tokyo University
Leads: Humanity & Health Medical Group Limited

This content was sourced from clinicaltrials.gov